Stocktoria
Scienture Holdings, Inc. SCNX
Scienture Holdings, Inc. (SCNX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It pays a dividend (safety: no dividend). FY2025 revenue was $431,609 at a -9618.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.062 |
| Retained earnings / assets | -0.957 |
| EBIT / assets | -0.506 |
| Equity / liabilities | 4.988 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SCNX | Scienture Holdings, Inc. | 4/9 | -0.88 | — | — |
| MNOV | MEDICINOVA INC | 1/9 | -18.54 | — | — |
| IBIO | iBio, Inc. | 3/9 | — | — | — |
| MREO | Mereo BioPharma Group plc | 3/9 | — | — | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | 2/9 | — | — | — |
| QUCY | Quantum Cyber N.V. | 3/9 | — | — | — |
| ALLR | Allarity Therapeutics, Inc. | 3/9 | — | — | — |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
FAQ
Is SCNX financially healthy?
Scienture Holdings, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SCNX pay a dividend, and is it safe?
Yes. Scienture Holdings, Inc. pays a dividend with a None payout ratio, rated “no dividend” for safety.
How profitable is SCNX?
In FY2025, Scienture Holdings, Inc. had a net margin of -9618.0% and a return on equity of -59.2%.
What is the analyst price target for SCNX?
The average Wall-Street price target for Scienture Holdings, Inc. is $1.50, about 233.3% above the recent price, from 1 analysts.
Is SCNX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Scienture Holdings, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.